Mehta Analysis: Trump Pricing Tempest In A Teapot Is An Opportunity For Bio-pharma Leaders

President Trump's much anticipated pronouncements on drug pricing reform leave a lot to be clarified. Biopharma companies and their leaders should grasp the opportunity to lead from the front and propose tangible and transformative actions that deliver benefits for all stakeholders. This may be one of the few letdowns that the biopharma industry should embrace, if not relish. Shrill propaganda by so many in the government, starting with President Trump himself soon after entering the US presidential race, had escalated…

Continue Reading
Close Menu